Testosterone undecanoate (Andriol Testocaps) cap 40 mg: Discontinuation
Merck Sharpe & Dohme has notified that it will discontinue the supply of testosterone undecanoate (Andriol Testocaps) cap 40 mg.
Stock likely to run out mid-2022
Pharmac is looking at alternatives to reduce any impact on patients. We will update this page as the situation evolves.
We want to ensure supply of testosterone undecanoate for existing patients for as long as possible. As such, we have restricted dispensing to people who were using testosterone undecanoate before 1 November 2021. Pharmacists can endorse the script where they have a record of a previous dispensing of testosterone undecanoate.
We acknowledge the inconvenience this may cause to patients, pharmacists and prescribers.
Alternatives to testosterone undecanoate
There are a number of fully funded testosterone treatments options available
Who to contact
If you are treated with Andriol Testocaps, talk to the person who prescribed the treatment. They know you and your clinical circumstances best and can advise you on whether you might need to change treatment.
If you have questions about the funding of testosterone products, email firstname.lastname@example.org